Indegene Ltd
NSE: INDGN BSE: 544172
₹571.90
-16.20 (2.75%)
Tue, 27 Oct 2026, 05:24 am
Market Cap (in Cr)13771.25
PE Ratio34.45
Dividend0.39
Health Technology
Pharmaceuticals: Major
24.5KIndegene Financials
| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Total revenue | 6.43B | 9.66B | 16.65B | 23.06B | 25.90B | 28.39B |
| Gross profit | 2.49B | 4.01B | 6.10B | 5.81B | 6.94B | 7.72B |
| Operating expenses (excl. COGS) | -1.24B | -1.95B | -3.54B | -2.42B | -2.56B | -3.15B |
| Selling/general/admin expenses, total | -1.24B | -1.94B | -3.52B | -2.39B | -2.57B | -3.04B |
| Research & development | — | — | — | — | — | — |
| Selling/general/admin expenses, other | -1.24B | -1.94B | -3.52B | -2.39B | -2.57B | -3.04B |
| Other operating expenses, total | 760.00K | -6.77M | -21.60M | -24.10M | 9.00M | -106.00M |
| Operating income | 1.25B | 2.06B | 2.56B | 3.39B | 4.38B | 4.57B |
| Non-operating income, total | -498.45M | 254.78M | -290.68M | 238.02M | 205.00M | 820.00M |
| Interest expense, net of interest capitalized | -88.35M | -69.57M | -59.63M | -313.32M | -494.00M | -220.00M |
| Interest capitalized | 0 | 0 | 0 | 0 | 0 | 0 |
| Non-operating income, excl. interest expenses | 26.50M | 212.07M | 237.94M | 551.34M | 615.00M | 878.00M |
| Non-operating interest income | 9.08M | 8.85M | 8.03M | 103.05M | 296.00M | 285.00M |
| Miscellaneous non-operating expense | 17.42M | 203.22M | 229.91M | 448.29M | 319.00M | 593.00M |
| Unusual income/expense | -436.60M | 112.28M | -468.99M | 0 | 84.00M | 162.00M |
| Pretax income | 752.72M | 2.32B | 2.26B | 3.63B | 4.59B | 5.39B |
| Taxes | -261.16M | -457.80M | -636.78M | -969.48M | -1.22B | -1.33B |
| Non-controlling/minority interest | 61.24M | -80.00K | 19.44M | 0 | 0 | 0 |
| After tax other income/expense | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income before discontinued operations | 558.08M | 1.86B | 1.65B | 2.66B | 3.37B | 4.07B |
| Net income | -62.99M | 1.49B | 1.65B | 2.66B | 3.37B | 4.07B |
| Dilution adjustment | 0 | 0 | 0 | 0 | 0 | 0 |
| Preferred dividends | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted net income available to common stockholders | -62.99M | 1.49B | 1.65B | 2.66B | 3.37B | 4.07B |
| Basic earnings per share (Basic EPS) | - | - | - | - | - | - |
| Diluted earnings per share (Diluted EPS) | - | - | - | - | - | - |
| EBITDA | 1.44B | 2.32B | 2.89B | 3.99B | 5.14B | 5.38B |
| EBIT | 1.25B | 2.06B | 2.56B | 3.39B | 4.38B | 4.57B |
| Total operating expenses | -5.18B | -7.60B | -14.09B | -19.67B | -21.52B | -23.82B |
| Prepaid expenses | 123.70M | 255.32M | 389.31M | 551.77M | 868.00M | 604.00M |
| Deferred income, current | 400.67M | 563.92M | 1.87B | 1.09B | 1.32B | 1.99B |
| Capital and operating lease obligations | 194.58M | 134.31M | 329.32M | 852.01M | 652.00M | 724.00M |
| Operating lease liabilities | — | — | — | — | — | — |
| Deferred tax liabilities | — | — | — | — | — | — |
| Deferred income, non-current | — | — | — | — | — | — |
| Minority interest | 890.82M | 85.75M | 0 | 0 | 0 | 0 |
| Change in accrued expenses | — | — | — | — | — | — |
| Common dividends paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Preferred dividends paid | 0 | 0 | 0 | 0 | 0 | 0 |
